Efficacy of the antimicrobial compound U-82,127 as a growth promoter for growing-finishing pigs.
The antimicrobial compound U-82,127 (Pharmacia & Upjohn, Kalamazoo, MI) is a thiopeptide that belongs to a series of cyclic peptide antibiotics produced by Streptomyces arginensis. It is active mainly against Gram-positive organisms. A study involving 576 growing-finishing pigs was conducted at six locations to assess the efficacy of the growth-promoting compound from approximately 19 to 89 kg BW. The basal diet was an unmedicated corn-soybean meal diet fortified with vitamins and trace minerals and containing 16% CP (.80% lysine) during the growing stage (to 54 kg) followed by 13% CP (.60% lysine) during the finishing stage. Dietary dose concentrations of the antimicrobial compound were 0, 3.3, 6.6, and 9.9 mg/kg. At each location, there were six replications of four pigs (two barrows and two gilts) per pen. Diets and water were available for ad libitum consumption. The antimicrobial was provided in coded bags, and investigators were blind to the treatments. The ADG during the growing stage was improved by all levels of the antimicrobial (P < .04), but only the 6.6 mg/kg level improved ADG during the finishing stage (P < .03). Feed:gain was improved by all concentrations of the antibiotic (P < .01) during the growing stage and by the two lower levels of the drug (P < .06) during the finishing stage. Over the entire study, the antimicrobial compound improved ADG (linear, P < .06) and feed:gain (quadratic, P < .01; minimum feed:gain was at 6.2 mg/kg). The lowest dose with a 90% confidence interval of its predicted value not overlapping with the predicted value of the control was 2.3 mg/kg; thus, the efficacious dose range for improving feed/gain was between 2.3 and 6.2 mg/ kg. Neither death loss nor pig removal from the experiment was affected by treatment. The results indicate that the antimicrobial compound U-82,127 is an effective growth-promoting agent for growing-finishing pigs.
Cromwell
G L
GL
Animal Sciences Department, University of Kentucky, Lexington 40546, USA.
Davis
G W
GW
Morrow
W E
WE
Primo
R A
RA
Rozeboom
D W
DW
Sims
M D
MD
Stanisiewski
E P
EP
Ho
C H
CH
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006133:Growth Substances / Q000494:pharmacology*; D008297:Male; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011897:Random Allocation; D013552:Swine / Q000254:growth & development*; D015430:Weight Gain / Q000187:drug effects
D000900:Anti-Bacterial Agents; D006133:Growth Substances; D010456:Peptides, Cyclic; C102859:Alexomycin